Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. (CTKB) delivers advanced cell analysis solutions through its patented Full Spectrum Profiling technology, serving research institutions and biotech organizations worldwide. This page provides investors and industry professionals with direct access to official company announcements and relevant news updates.
Discover the latest developments including product innovations, financial results, strategic partnerships, and regulatory milestones. Our curated collection ensures you stay informed about CTKB’s progress in advancing high-resolution cellular analysis tools for scientific research.
Key updates cover earnings reports, technology enhancements, executive leadership changes, and market expansion initiatives. All content is sourced from verified channels to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Cytek Biosciences’ evolving story in life sciences innovation. Check back regularly for real-time updates that matter to stakeholders in the biotech investment community.
Amberstone Biosciences has successfully completed a $12 million Series A financing round, led by Viva BioInnovator, Co-win Ventures, and Sinovation Ventures, among others. The funds will be utilized to advance their tumor microenvironment activated therapeutic programs to the investigational new drug application (IND) enabling stage. CEO George Wu expressed gratitude for investor support, emphasizing their goal of developing safer and more effective therapies for cancer patients.
Cytek Biosciences (Nasdaq: CTKB) celebrated a major milestone by shipping its 1,000th cell analysis system, highlighting global adoption across 35 countries since launching in 2017. The company has expanded its product range with new high-dimensional sorters and immunoprofiling kits, enhancing research capabilities in immunology and oncology. Cytek's growth is supported by new offices in the US and Europe, following its IPO in July 2021. The company emphasizes its commitment to advancing flow cytometry technology for improved patient outcomes.
Cytek Biosciences (Nasdaq: CTKB) reported a 37% increase in third quarter total revenue, reaching $34.4 million, compared to the same period in 2020. The company expanded its installed base to 970 instruments with 115 placements during the quarter. Cytek launched a new 25-color immunoprofiling assay and acquired the cell analysis business of Tonbo Biosciences. Despite revenue growth, net income fell to $1.6 million from $6.5 million and operating expenses surged 106% to $18.3 million.
Cytek Biosciences (Nasdaq: CTKB) has announced the acquisition of the cell analysis business from Tonbo Biosciences. This acquisition expands Cytek's portfolio with life science research reagents related to cell preparation, molecular immunology, and flow cytometry. The integration of Tonbo’s reagents into Cytek's existing offerings aims to enhance its flow cytometry capabilities, particularly in protein and cell analysis. This strategic move reflects Cytek's commitment to delivering comprehensive solutions in the cell analysis market.
Cytek Biosciences (Nasdaq: CTKB) announced it will release its third-quarter 2021 financial results on November 8, 2021, after market close. A conference call will follow at 1:30 PM PT to discuss the results and future outlook. Cytek is recognized for its innovation in cell analysis technologies, specifically its Full Spectrum Profiling™ (FSP™) platform, which supports advanced cellular analysis through high-resolution and high-sensitivity tools. The company's offerings include the Aurora and Northern Lights systems, with products primarily for research use, except for limited clinical applications in China and the EU.
Cytek Biosciences (Nasdaq: CTKB) launched a new 25-color immunoprofiling assay optimized for the Aurora full spectrum flow cytometer. This assay simplifies workflows from sample preparation to data analysis, aiding in immunology research for vaccines and therapies. It identifies key immune cell populations and is complemented by an 18-color cFluor reagent kit. Dr. Wenbin Jiang emphasized the company's commitment to accelerating immunology discoveries. The assay features user-friendly protocols to enhance laboratory efficiency, advancing research on T, B, NK cells, and more.
Cytek Biosciences announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 2:00 p.m. PT. Interested parties can access the live and archived webcast through the company's Investors section of their website.
Cytek specializes in cell analysis solutions, utilizing its proprietary Full Spectrum Profiling™ (FSP™) technology for highly sensitive and multiplexed cell analysis. Their core products include the Aurora and Northern Lights™ systems, and they operate globally from their headquarters in Fremont, California.
Cytek Biosciences (Nasdaq: CTKB) reported a strong second quarter for 2021, achieving total revenue of $30.4 million, a 59% increase from Q2 2020. The company expanded its installed base to 855 instruments, adding 104 placements during the quarter. Gross profit surged by 137% to $19.7 million, with a 65% gross profit margin. Operating expenses rose by 87% to $15.9 million, mainly due to product development and increased headcount. Despite these expenses, net income stood at $2.7 million for Q2 2021, down from $8.1 million in the previous year.
Cytek Biosciences, a leader in cell analysis solutions, announced that underwriters fully exercised their option to purchase an additional 2,184,695 shares at $17.00 per share. This brings the total shares sold in its recent IPO to 16,749,330, generating $237 million in gross proceeds before expenses. The IPO, completed on July 27, 2021, included shares sold by both Cytek and certain stockholders. Joint book-running managers for the offering were Morgan Stanley, Goldman Sachs, Piper Sandler, and Cowen.
Cytek Biosciences announced the closing of its initial public offering, raising $200 million by selling 14,564,635 shares at $17.00 per share. The offering included 11,764,706 shares from Cytek and 2,799,929 shares from selling stockholders. Cytek did not receive proceeds from the latter. Additionally, underwriters were granted a 30-day option to purchase 2,184,695 shares to cover over-allotments. Shares are traded on Nasdaq under the symbol CTKB.
